

DRUG NAME: Zoledronic acid**SYNONYM(S):** CGP-42446¹**COMMON TRADE NAME(S):** ZOMETA®**CLASSIFICATION:** bone metabolism regulator*Special pediatric considerations are noted when applicable, otherwise adult provisions apply.***MECHANISM OF ACTION:**

Zoledronic acid is a third generation, nitrogen containing bisphosphonate that inhibits bone resorption. It binds to hydroxyapatite crystals of the bone where it accumulates and is stored as an inactive drug. Zoledronic acid can persist for years in mineralized bone until it is released into systemic circulation once bone resorption occurs.^{2,3} When ingested by osteoclasts, it inhibits osteoclastic formation, recruitment, activity, and induces osteoclast apoptosis.^{1,4} In preclinical models, zoledronic acid prevents tumour adhesion to the bone, induces tumour cell apoptosis, and inhibits angiogenesis.⁵ Zoledronic acid is structurally similar to pamidronate, but is 100-850 times more potent and is associated with higher binding affinity to bone and higher antiresorptive potential.^{1,5-7}

PHARMACOKINETICS:

Distribution	low affinity for the cellular components of human blood; binds to bone	
	cross blood brain barrier?	no information found
	volume of distribution	no information found
	plasma protein binding ^{6,8}	23-55%
Metabolism	does not undergo metabolism	
	active metabolite(s)	no
	inactive metabolite(s)	no
Excretion	eliminated intact via the kidney	
	urine	39%
	feces	< 3%
	terminal half life	146 hours
	clearance	3.7 L/h
Ethnicity	Japanese females had substantially higher systemic exposure than North Americans in a single-dose pharmacokinetic study (47% higher AUC and 39% higher C _{max}); exposure in Japanese males was comparable to the North American population	

Adapted from standard reference⁶ unless specified otherwise.**USES:****Primary uses:**

- *Hypercalcemia of malignancy
- *Bone metastases of solid tumours
- *Multiple myeloma
- *Health Canada approved indication

Other uses:

- Breast cancer^{9,10}
- Prevention of bone loss^{11,12}

SPECIAL PRECAUTIONS:**Contraindications:**

- do NOT use in patients who have a history of **hypersensitivity reaction** to zoledronic acid or other bisphosphonates⁶

Caution:

- osteonecrosis of the jaw (ONJ)** has been reported with zoledronic acid; patients receiving anti-angiogenic drugs may be at higher risk¹³⁻¹⁶
- correct preexisting **hypocalcemia** prior to treatment and ensure adequate calcium and vitamin D intake⁸
- ZOMETA® contains the **same active ingredient** as ACLASTA® but they are **NOT interchangeable**; formulations differ in concentration, dose, and indication⁶

Special populations: Safety in children has not been established. In animal studies, an increased incidence of primary spongiosa was reported in the long bones of growing animals.⁶

Carcinogenicity: No evidence of carcinogenic potential in animal studies.⁶

Mutagenicity: Not mutagenic in Ames test and mammalian *in vitro* mutation test; not clastogenic in mammalian *in vitro* and *in vivo* chromosome tests.⁶

Fertility: Animal studies demonstrated reduced fertility, including increased pre- and post-implantation losses and a decreased number of live fetuses at doses lower than the equivalent human systemic exposure.⁶

Pregnancy: The potential risk to humans is unknown; however in animal studies, zoledronic acid crossed the placental barrier, was taken up into the developing fetal skeleton, and caused external, visceral, and skeletal malformations. In addition, increased maternal mortality was observed, possibly related to drug-induced inhibition of skeletal calcium mobilization, resulting in periparturient hypocalcemia. As zoledronic acid is incorporated into the bone matrix and is gradually released over weeks to years, the amount of time required to reduce the risk of fetal harm after cessation of therapy is unknown. Zoledronic acid is not recommended during pregnancy.^{4,6,13}

Breastfeeding is not recommended due to the potential secretion into breast milk. Animal studies have shown that other bisphosphonates are detected in the milk of lactating animals. Because zoledronic acid is released from the bone over weeks to years, there may be an ongoing risk to infants born post bisphosphonate therapy.^{4,6}

SIDE EFFECTS:

The table includes adverse events that presented during drug treatment but may not necessarily have a causal relationship with the drug. Because clinical trials are conducted under very specific conditions, the adverse event rates observed may not reflect the rates observed in clinical practice. Adverse events are generally included if they were reported in more than 1% of patients in the product monograph or pivotal trials, and/or determined to be clinically important.^{17,18} When placebo-controlled trials are available, adverse events will generally be included if the incidence is $\geq 5\%$ higher in the treatment group.^{19,20}

ORGAN SITE	SIDE EFFECT
Clinically important side effects are in bold, italics	
blood and lymphatic system/ febrile neutropenia	anemia (33%)
cardiac	arrhythmia (<1%)
	atrial fibrillation (<1%)
eye	conjunctivitis, uveitis, episcleritis, scleritis, orbital inflammation (<1%)

ORGAN SITE	SIDE EFFECT
Clinically important side effects are in bold, italics	
gastrointestinal	<i>emetogenic potential: rare</i> ^{17,21,22}
	constipation (27%) ¹³
	diarrhea (24%)
	nausea (6-12%) ²³
	stomatitis (8%) ¹³
	vomiting (2%) ²⁴
general disorders and administration site conditions	<i>extravasation hazard: none</i> ²⁵
	fatigue (39%)
	pyrexia (32-44%) ^{6,13} ; see paragraph following Side Effects table
	rigors (11%) ¹³
immune system	hypersensitivity reaction (<1%) ¹³
injury and poisoning	atypical bone fracture (<1%); see paragraph following Side Effects table
investigations	creatinine increase (severe 2%)
metabolism and nutrition	hypocalcemia (5%); see paragraph following Side Effects table
	hypokalemia (10%)
	hypomagnesemia (11%) ¹³
	hypophosphatemia (13%) ¹³
musculoskeletal and connective tissue (see paragraph following Side Effects table)	arthralgia (21%)
	back pain (15%)
	bone pain (<1%)
	myalgia (23%)
	osteonecrosis of the jaw (1% during first year of treatment, 4% cumulative incidence) ^{26,27}
nervous system	headache (19%)
	dizziness (18%)
	paresthesia (15%)
psychiatric	agitation (13%) ¹³
	anxiety (14%) ¹³
	depression (14%)
	insomnia (15%) ¹³
renal and urinary	renal impairment (10-17%); see paragraph following Side Effects table
respiratory, thoracic and mediastinal	cough (22%)
	interstitial lung disease (<1%)
skin and subcutaneous tissue	rash, pruritis (<1%)
vascular	hypotension (1-11%) ^{6,13}

Adapted from standard reference⁶ unless specified otherwise.

Atypical bone fractures (subtrochanteric and diaphyseal femur) are reported rarely in patients on long-term bisphosphonate therapy. These fractures often occur with minimal or no trauma and are slow to heal. Patients may experience prodromal pain for weeks or months before a fracture occurs and imaging often reveals stress fractures weeks to months prior to patients presenting with a completed femoral fracture. Assess both limbs in patients who present with thigh or groin pain because femoral fractures are often bilateral. Discontinue therapy if a femoral shaft fracture is confirmed.^{4,8}

Flu-like symptoms caused by an acute phase reaction commonly occur within one to three days after administration of zoledronic acid, especially during the first few infusions. **Pyrexia** is the most common symptom, but myalgia, arthralgia, arthritis, swollen joints, and/or headache may also occur. There are no criteria to identify patients at risk, so routine prophylaxis is not recommended. Acetaminophen and oral fluids may help reduce flu-like symptoms if they occur. The symptoms are usually self-limiting, resolving within a few days to a few weeks.^{4,6,13,22}

Severe, **incapacitating bone, joint, and/or muscle pain** has occurred within days to months of starting therapy. This severe pain is a syndrome distinct from the acute phase reaction. For some patients the pain is so severe they are unable to continue their normal activities of daily living and may require aids for walking. There are no known risk factors for this debilitating pain. Most patients have relief of symptoms after stopping drug therapy; however some patients report slow or incomplete pain resolution. Temporary or permanent discontinuation of the drug may be required as symptoms have reoccurred in a subset of patients rechallenged with zoledronic acid or another bisphosphonate.⁶

Hypocalcemia is reported and has been life-threatening in some cases. Neurologic adverse events (e.g., tonic-clonic seizures, tetany, and numbness) as well as QTc prolongation and cardiac arrhythmias secondary to severe hypocalcemia may occur. Onset of secondary effects may occur as soon as one day to several months after initiation of therapy. People who have calcium and mineral metabolism disturbances (e.g., hypoparathyroidism, thyroid/parathyroid surgery) may be particularly susceptible to developing hypocalcemia. Measure albumin-corrected serum calcium before treatment and correct calcium levels before administering zoledronic acid. Consider calcium and vitamin D supplementation during therapy. Symptoms of muscle spasms, numbness, and/or tingling, especially around the mouth should be promptly reported.^{4,6,8}

Osteonecrosis of the jaw (ONJ) is a rare, but serious event that has been associated with antiresorptive agents such as bisphosphonate therapy. Osteonecrosis of other anatomical sites (e.g., femur, hip, auditory canal, metatarsal bones, etc.) have also been rarely reported.⁶ ONJ is more commonly observed with increasing bisphosphonate potency, dose intensity, and duration of treatment, particularly when treatment exceeds four years.²⁶⁻²⁸ The risk of ONJ is higher with intravenous than with oral bisphosphonate treatment.^{29,30} Multiple risk factors may play a role, including invasive dental procedures and pre-existing dental disease,^{27,31} concomitant therapy with angiogenesis inhibitors, corticosteroids, and radiation to the head and neck^{26,27,29,30}, as well as certain comorbid medical conditions (e.g., anemia^{29,31}, cancer^{26,30}, coagulopathies²⁹, and diabetes^{26,32}). For further details and management of ONJ, refer to *Bisphosphonates and Osteonecrosis of the Jaw* in [Oral & Dental Care: Osteonecrosis of the Jaw](#).

Renal toxicity resulting in renal failure, dialysis, and/or death has been reported in patients with both normal and impaired renal function. Because zoledronic acid is excreted exclusively by the kidney, the risk of adverse reactions may be greater in patients with pre-existing renal impairment. Other risk factors include; dehydration, advanced age, concomitant nephrotoxic drugs or drugs that significantly impact renal function, prior bisphosphonate use, and/or multiple bisphosphonate cycles. To avoid inducing renal toxicity, zoledronic acid dose should not exceed 4 mg and the duration of infusion should be no less than 15 minutes. Assess renal function prior to and during therapy and withhold zoledronic acid for renal deterioration. If appropriate, zoledronic acid may be resumed at the same dose used prior to dose interruption if renal function returns to within 10% of baseline. Rarely, serious cases of acquired **Fanconi syndrome** have been reported. Symptoms include hyperaminoaciduria, glucosuria in the presence of normal serum glucose, and phosphaturia. Discontinue zoledronic acid in the setting of Fanconi syndrome.^{4,8}

INTERACTIONS: No documented interactions reported.⁶

SUPPLY AND STORAGE:***Injection:***

Novartis Pharmaceuticals Canada Inc. supplies zoledronic acid as 4 mg single-use (preservative-free) vials in a concentration of 0.8 mg/mL. Store at room temperature.⁶

Dr. Reddy's Laboratories Limited (distributed by Innomar Strategies Inc.) supplies zoledronic acid as 4 mg single-use (preservative-free) vials in a concentration of 0.8 mg/mL. Store at room temperature.³³

Sandoz Canada Inc. supplies zoledronic acid as 4 mg single-use (preservative-free) vials in a concentration of 0.8 mg/mL. Store at room temperature.³⁴

For basic information on the current brand used at BC Cancer, see [Chemotherapy Preparation and Stability Chart](#) in Appendix.

SOLUTION PREPARATION AND COMPATIBILITY:

For basic information on the current brand used at BC Cancer, see [Chemotherapy Preparation and Stability Chart](#) in Appendix.

Additional information: Do NOT reconstitute or dilute with calcium-containing solutions (e.g., lactated Ringer's solution) or other divalent cation-containing infusion solutions.¹³

Compatibility: consult detailed reference

PARENTERAL ADMINISTRATION:

BC Cancer administration guideline noted in ***bold, italics***

Subcutaneous	no information found
Intramuscular	no information found
Direct intravenous	Do NOT use
<i>Intermittent infusion⁶</i>	<i>over at least 15 minutes</i>
Continuous infusion	no information found
Intraperitoneal	no information found
Intrapleural	no information found
Intrathecal	no information found
Intra-arterial	no information found
Intravesical	no information found

DOSAGE GUIDELINES:

Refer to protocol by which patient is being treated. Numerous dosing schedules exist and depend on disease, response, and concomitant therapy. Dosage may be reduced, delayed or discontinued.

Adults:

BC Cancer usual dose noted in ***bold, italics***

Intravenous: Cycle Length:
3-4 weeks⁶: 4 mg (range 3-4 mg) IV for one dose on day 1
(total dose per cycle 4 mg [range 3-4 mg])

BC Cancer usual dose noted in ***bold, italics***

Cycle Length:
12 weeks³⁵⁻³⁷: **4 mg** (range 3-4 mg) ***IV for one dose on day 1***
 (total dose per cycle 4 mg [range 3-4 mg])

6 months^{9,38,39}: **4 mg IV for one dose on day 1**
 (total dose per cycle 4 mg)

for hypercalcemia of malignancy Refer to BC Cancer Protocol SCHYPCAL: Guidelines for the Diagnosis and Management of Malignancy Related Hypercalcemia at [Chemotherapy Protocols – Supportive Care](#)

Concurrent radiation: no information found

Dosage in renal failure⁶: suggested dose modification:

Creatinine clearance (mL/min)	Dose
>60	4 mg
50-60	3.5 mg
40-49	3.3 mg
30-39	3 mg
<30	not recommended

Calculated creatinine clearance = $\frac{N^* \times (140 - \text{Age}) \times \text{weight in kg}}{\text{Serum Creatinine in } \mu\text{mol/L}}$

* For males N=1.23; for females N=1.04

for hypercalcemia of malignancy (refer to BC Cancer Protocol SCHYPCAL)⁸:

- mild to moderate impairment: no dose adjustment
- severe impairment (serum creatinine > 400 $\mu\text{mol/L}$): no information

Dosage in hepatic failure: no information found

Dosage in dialysis: no information found

Children: not indicated for use in children^{6,13}

REFERENCES:

1. Body JJ. Clinical research update: Zoledronate. Cancer 1997;80(S8):1699-1701.
2. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin.Proc. 2008;83(9):1032-1045.
3. Green SB, Pappas AL. Effects of maternal bisphosphonate use on fetal and neonatal outcomes Am J Health Syst Pharm 2014 ;71(23):2029-2036.
4. AHFS Drug Information® (database on the Internet). Zoledronic Acid. Lexi-Comp Inc., 11 March 2016. Available at: <http://online.lexi.com>. Accessed 11 January 2017.
5. Valachis A, Polyzos NP, Coleman RE, et al. Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis. Oncologist 2013;18:353-361.
6. Novartis Pharmaceuticals Canada Inc. ZOMETA® product monograph. Dorval, Quebec; 12 August 2016.
7. Gnant M. Zoledronic acid in breast cancer: latest findings and interpretations. Ther Adv Med Oncol 2011;3(6):293-301.
8. Lexicomp Online® (database on the Internet). Zoledronic Acid. Lexi-Comp Inc., 3 January 2017. Available at: <http://online.lexi.com>. Accessed 11 January 2017.
9. Gnant M, Mlineritsch B, Stoeger H, et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozole plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol 2015;26:313-320.
10. Coleman R, de Boer R, Eidtmann H, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann.Oncol. 2013;24(2):398-405.
11. Michaelson MD, Kaufman DS, Lee H, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist–induced bone loss in men with prostate cancer. J Clin Oncol 2007;25:1038-1042.

12. Brufsky AM, Harker WG, Beck JT, et al. Final 5-year results of Z-FAST trial. *Cancer* 2012;118:1192-1201.
13. Novartis Pharmaceuticals Corporation. ZOMETA® full prescribing information. East Hanover, NJ, USA; March 2016.
14. Lescaille G, Coudert AE, Baaroun V, et al. Clinical study evaluating the effect of bevacizumab on the severity of zoledronic acid-related osteonecrosis of the jaw in cancer patients. *Bone* 2014;58:103-107.
15. Fusco V, Porta C, Saia G, et al. Osteonecrosis of the jaw in patients with metastatic renal cell cancer treated with bisphosphonates and targeted agents: results of an Italian multicenter study and review of the literature. *Clin Genitourin Cancer* 2015;13(4):287-294.
16. Smidt-Hansen T, Folkmar TB, Fode K, et al. Combination of zoledronic acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma. *J Oral Maxillofac Surg* 2013;71:1532-1540.
17. Sophie Sun MD. Personal communication. BC Cancer Agency Breast Tumour Group; 21 August 2017.
18. Khushminder Rai. Personal communication. Pharmacist, BC Cancer Agency Breast Tumour Group; 27 February 2017.
19. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. *JNCI Cancer Spectrum* 2002;94(19):1458-1468.
20. Rosen LS, Gordon D, Tchekmedyan S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. *J Clin Oncol* 2003;21(16):3150-3157.
21. BC Cancer Agency. (SCNAUSEA) Guidelines for Prevention and Treatment of Chemotherapy-induced Nausea and Vomiting in Adults. Vancouver, British Columbia: BC Cancer Agency; 1 Mar 2012.
22. Berenson JR. Recommendations for zoledronic acid treatment of patients with bone metastases. *Oncologist* 2005;10:52-62.
23. Gnant M, Mlineritsch B, Stoeger H, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. *Lancet Oncol* 2011;12(7):631-641.
24. Coleman R, Cameron D, Dodwell D, et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. *The Lancet Oncology* 2014;15(9 Suppl 1):S1-19.
25. BC Cancer Agency Provincial Systemic Therapy Program. Provincial Systemic Therapy Program Policy III-20: Prevention and Management of Extravasation of Chemotherapy. Vancouver, British Columbia: BC Cancer Agency; January 2016.
26. Berenson JR, Stopeck AT. Medication-related osteonecrosis of the jaw in patients with cancer. In: 2017 UpToDate®; Savarese, Diane MF. (Ed); Waltham, Massachusetts: UpToDate®; Available at www.uptodate.com; updated 3Feb2017; accessed 13Mar2017.
27. Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update. *J. Oral Maxillofac. Surg* 2014;72(10):1938-1956.
28. Hoff AO, Toth BB, Altundag A, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. *J Bone Miner Res* 2008;23:826-836.
29. Health Canada. MedEffect® summary safety review: assessing the risk of jaw bone loss (osteonecrosis of the jaw). 25 November 2016. Available at: <http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/bisphosphonates-eng.php>. Accessed 4 January 2017.
30. European Medicines Agency. News and Press Releases: Further measures to minimise risk of osteonecrosis of the jaw with bisphosphonate medicine. 27 March 2015. Available at: <http://www.ema.europa.eu/ema/>. Accessed 20 March 2017.
31. Saad F, Brown JE, Van Poznak C, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. *Ann Oncol* 2012;23(5):1341-1347.
32. Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. *J Bone Miner Res* 2015;30(1):3-23.
33. Innomar Strategies Inc. (for Dr. Reddy's Laboratories Limited). Zoledronic acid for injection concentrate® product monograph. Oakville, Ontario; 11 March 2015.
34. Sandoz Canada Inc. Zoledronic Acid - Z® product monograph. Boucherville, Quebec; 02 December 2016.
35. Hortobagyi GN, Van Poznak C, Harker WG, et al. Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone: the OPTIMIZE-2 randomized clinical trial. *JAMA Oncol*. 2017.
36. BC Cancer Agency Breast Tumour Group. (UBRAVZOL) BCCA Protocol Summary for Treatment of Acute Bone Pain Secondary to Breast Cancer Metastases using IV Zoledronic Acid. Vancouver, British Columbia: BC Cancer Agency; 1 September 2017.
37. Amadori D, Aglietta M, Alessi B, Gianni L, et al. Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial *Lancet Oncol* 2013 ;14(7):663-670.
38. Coleman R, Cameron D, Dodwell D, et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. *Lancet Oncol* 2014;15(9):997-1006.
39. BC Cancer Agency Breast Tumour Group. (BRAJZOL) BCCA Protocol Summary for Adjuvant Treatment of Post-menopausal Women Using Zoledronic Acid. Vancouver, British Columbia: BC Cancer Agency; 1 December 2017.